Ursula A. Matulonis, MD
Ursula A. Matulonis, MD
Medical Director
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston,
MA
USA
02215
Papers:
13
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy
14
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study sub-analysis
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP-inhibitor Resistance